$CDLX

Gupta Amit sold $71K of CDLX

Gupta Amit (Chief Executive Officer) sold 16,138 shares of Cardlytics, Inc. (CDLX) at an average of $4.39 ($4.39–$4.40) across 2 trades over 2026-07-02 to 2026-07-06.

Original reporting
SEC EDGAR · Gupta Amit
Published Jul 6, 2026, 9:52 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 6, 2026, 9:53 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CDLX
Neutral
medium confidence
Mentioned
$CDLX
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CDLXNeutralLow
01

Why it matters

Traders may monitor for follow-on insider activity, but the disclosure alone does not change the company’s earnings outlook or business trajectory based on the provided text.

02

Market read

A new Form 4 insider sale was disclosed, which can slightly influence sentiment but is not a fundamental catalyst in the article.

03

What to watch

The article does not state whether the sale was part of a broader pattern, tax event, or compensation schedule; it also lacks any context on total insider holdings changes beyond the post-trade figure.

Relevance 3/10Novelty 5/10Timing: Filed 2026-07-06 after-hours (SEC Form 4 disclosure).

Background

The article is a primary-source SEC Form 4 insider transaction for Cardlytics, Inc. (CDLX).

Company-level read

Ticker impact

$CDLXNeutralMedium confidence
Context

Cardlytics CEO Amit Gupta filed a Form 4 selling 16,138 shares in open-market trades at about $4.3944/share.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and typically fades unless repeated or paired with other disclosures.

Evidence & confidence

The filing is a routine open-market sale (no 10b5-1 plan stated) with small-to-moderate dollar value and no accompanying company-specific fundamental catalyst in the text.

Market effects

No sector read-across; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for liquidity/tax and do not necessarily signal deteriorating fundamentals, especially when the filing is routine.

Key entities

  • Cardlytics, Inc.

    Subject of the Form 4 insider transaction; CEO Amit Gupta sold shares in open-market trades.

  • Amit Gupta

    CEO of Cardlytics; reported open-market sale of 16,138 shares at ~$4.3944/share.

Related articles

$CDLXMedAI 8/10

Cardlytics: Q2 Earnings Snapshot

Cardlytics (CDLX) reported a Q2 loss of $14.9 million, or $2.58 per share. Adjusted for discontinued operations, the loss was $1.50 per share. Revenue was $36.9 million. For the quarter ending September, the company expects revenue of $34 million to $39 million.

$CDLXMed

Cardlytics, Inc. (CDLX): Results of Operations and Financial Condition

Cardlytics, Inc. (CDLX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cdlx_form8-kx2026q2xex991.htm EX-99.1 Document Exhibit 99.1 Cardlytics Second Quarter 2026 Financial Results Driven By Strong Operational Performance • Company delivers strong second quarter results: ◦ Revenues of $36.9 million ◦ Billings of $65.5 million ◦ Adjusted Con